Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.80 |
| ▸ | POLB | P06746 | 2/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | HTT | P42858 | 2/20 | 0.71 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | ATM | Q13315 | 1/20 | 0.69 |
| ▸ | CA9 | Q16790 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 2/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3659182 | 0.94 | ALDH1A1 (0.88) | ALDH1A1CYP19A1POLBTSHRHTT | |
| SCHEMBL12793674 | 0.86 | ALDH1A1 (0.78) | ALDH1A1CYP19A1POLBTSHRHTT | |
| SCHEMBL19636581 | 0.86 | ALDH1A1 (1.00) | ALDH1A1CYP19A1TSHRHTTCA12 | |
| SCHEMBL13310570 | 0.86 | ALDH1A1 (0.78) | ALDH1A1CYP19A1POLBTSHRHTT | |
| SCHEMBL22234016 | 0.85 | ALDH1A1 (0.74) | ALDH1A1CYP19A1POLBTSHRHTT | |
| SCHEMBL6272107 | 0.84 | ALDH1A1 (0.76) | ALDH1A1CYP19A1TSHRHTTSMN1; SMN2 | |
| SCHEMBL7109149 | 0.84 | ALDH1A1 (1.00) | ALDH1A1POLBSMN1; SMN2PKM | |
| SCHEMBL3914871 | 0.84 | ALDH1A1 (0.76) | ALDH1A1CYP19A1TSHRHTTL3MBTL1 | |
| SCHEMBL1893565 | 0.84 | ALDH1A1 (0.76) | ALDH1A1CYP19A1TSHRHTTCA9 | |
| SCHEMBL13419650 | 0.84 | ALDH1A1 (0.76) | ALDH1A1CYP19A1TSHRHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117964526-A | Synthesis and application of (4-benzyl (p-toluenesulfonyl) amino) benzenesulfonamide compound | 赣南医学院 | 2024-05-03 | — | — | CN | disclosed |
| CN-112047865-B | Method for synthesizing N-alkyl sulfonamide in water | 南京理工大学 | 2022-12-02 | — | — | CN | disclosed |
| CN-106279044-B | Pyrimidine hydroxamic acid derivative and preparation method and application thereof | 厦门市博瑞来医药科技有限公司 | 2021-02-19 | — | — | CN | disclosed |
| CN-112047865-A | Method for synthesizing N-alkyl sulfonamide in water | 南京理工大学 | 2020-12-08 | — | — | CN | disclosed |
| CN-104418678-B | A kind of method of synthetic N-alkyl sulfonamide derivatives | NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2016-05-18 | — | — | CN | disclosed |
| CN-104418678-A | Method for synthesizing N-alkyl sulfonamide derivative | UNIV NANJING SCIENCE & TECH | 2015-03-18 | — | — | CN | disclosed |
| US-20120094964-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2424517-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RaQualia Pharma Inc (JP) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010125831-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2010-11-04 | — | — | WO | disclosed |
| US-7348017-B2 | Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin | SHISEIDO CO., LTD. (JP) | 2008-03-25 | — | — | US | disclosed |
| WO-1998016503-A2 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1998-04-23 | — | — | WO | disclosed |
| WO-1998016514-A1 | ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1998-04-23 | — | — | WO | disclosed |
| EP-0801083-A2 | Improved functionalized resin for chemical synthesis | PFIZER INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| EP-0606046-B1 | Arylsulfonamido-substituted hydroxamic acids | CIBA GEIGY AG (CH) | 1997-10-08 | — | — | EP | disclosed |
| US-5672615-A | MATRIX-DEGRADING METALLOPROTEINASE INHIBITORS | NOVARTIS CORPORATION (US) | 1997-09-30 | — | — | US | disclosed |
| US-5646167-A | ADMINISTERED AS METALLOPROTEINASE INHIBITOR, ANTITUMOR OR ANTICARCINOGENIC AGENT | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5552419-A | METALLOPROTEINASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1996-09-03 | — | — | US | disclosed |
| US-5506242-A | METALLOELASTASE INHIBITOR; TREATS EMPHYSEMA | CIBA-GEIGY CORPORATION (US) | 1996-04-09 | — | — | US | disclosed |
| US-5455258-A | Useful as inhibitors of matrix-degrading metalloproteinase enzymes such as stromelysin and/or collegenase | CIBA-GEIGY CORPORATION (US) | 1995-10-03 | — | — | US | disclosed |
| EP-0606046-A1 | Arylsulfonamido-substituted hydroxamic acids | CIBA-GEIGY AG (CH) | 1994-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094964-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | TRPM8, TRPM5, TRPM6 | ALDH1A1 1996/4885CYP19A1 3568/4885POLB 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.